Texas A&M Develops Parkinson's Model
Analysis based on 13 articles · First reported Jun 29, 2026 · Last updated Jun 30, 2026
The development of a new, more accurate animal model for Parkinson s disease by Texas A&M University could significantly impact the biotechnology and pharmaceutical industries by accelerating drug discovery and therapeutic development for this widespread neurodegenerative disorder. This breakthrough may lead to increased investment in companies focused on Parkinson's research and treatment.
Researchers at Texas A&M University, led by Candice Brinkmeyer-Langford, have developed an innovative animal model for studying Parkinson s disease. This new model utilizes infection with Theiler s murine encephalomyelitis virus (TMEV), a natural pathogen in mice, to nontoxically induce brain damage and physical disabilities similar to those seen in human Parkinson's patients. This approach offers a significant improvement over traditional models that rely on gene modifications or toxicant injections, which may not accurately reflect the disease's natural progression. The study, supported by the United States — National Institute of Neurological Disorders and Stroke and published in Brain, Behavior, and Immunity - Health, confirmed that TMEV infection leads to the destruction of dopamine-producing brain cells and subsequent motor skill impairments. This breakthrough is expected to facilitate future research into early warning signs, biological markers, and immune responses related to Parkinson's, a disease affecting over 10 million people worldwide.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard